ArticleJournal of investigative medicine high impact case reports
Epstein-Barr Virus Coinfection in COVID-19.
Article in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Viral reactivations and co-infections in COVID-19 patients: a systematic review.BMC infectious diseases · 2023Pooled it
- Epstein-barr virus super-infection is associated with increased severity of hemorrhagic fever with renal syndrome.BMC infectious diseases · 2026Article
- Investigation of Epstein-Barr virus coinfection and changes in the gene expression of angiotensin converting enzyme II in peripheral blood mononuclear cells in COVID-19 patients.Biochemistry and biophysics reports · 2025Article
- Hepatocellular jaundice in SARS-CoV-2 and EBV coinfection: a case report.Virology journal · 2025Article
- Reactivation of Latent Tuberculosis Following COVID-19 and Epstein-Barr Virus Coinfection: A Case Report.Pathogens (Basel, Switzerland) · 2025Article
- GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection.Archives of virology · 2024Review
- Chronic active Epstein-Barr virus infection with reinfection of SARS-CoV-2: a case report.Virology journal · 2024Article
- Risk prediction for liver injury in Epstein-Barr virus infection in pediatric respiratory tract infections.Italian journal of pediatrics · 2023Article
- Reactivation of Epstein-Barr virus in SFTSV infected patients.Infectious medicine · 2023Article
- SARS-CoV-2 Induced Herpes Virus Reactivations and Related Implications in Oncohematology: When Lymphocytopenia Sets in and Immunosurveillance Drops Out.Microorganisms · 2023Article
- The Impact of Coronavirus Disease 2019 on Viral, Bacterial, and Fungal Respiratory Infections.Clinics in chest medicine · 2023Review
- May 2022 acute hepatitis outbreak, is there a role for COVID-19 and other viruses?World journal of hepatology · 2023Review
- Epidemiology and clinical characteristics of Epstein-Barr virus infection among children in Shanghai, China, 2017-2022.Frontiers in cellular and infection microbiology · 2023Article
- Urgency and necessity of Epstein-Barr virus prophylactic vaccines.NPJ vaccines · 2022Review
- SARS-CoV-2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?Journal of medical virology · 2022Review
- Distribution of Viral Respiratory Infections during the COVID-19 Pandemic Using the FilmArray Respiratory Panel.Biomedicines · 2022Article
- Article
- Resurrecting Epstein-Barr Virus.Pathogens (Basel, Switzerland) · 2022Article
- How Does Epstein-Barr Virus Interact With Other Microbiomes in EBV-Driven Cancers?Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV), a member of the herpes virus family, is a causative agent for infectious mononucleosis in young adults. It has an asymptomatic and subclinical distribution in about 90% to 95% of the world population based on seropositivity. EBV is associated with various lymphomas, nasopharyngeal carcinoma, and in immunocompromised states can give rise to aggressive lymphoproliferative disorders. Symptomatic patients mostly present with mild hepatitis, rash, oral symptoms, lymphadenopathy, and generalized malaise. Recently with the COVID-19 (coronavirus disease-2019) pandemic, hepatitis has been found to be related to acute EBV and cytomegalovirus reactivation versus acute infection in the absence of other major causes. We describe a case of EBV coinfection in a patient with resolving mild COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.